This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (25)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Thomas Ruzicka, MD; Michael Meurer, MD; Thomas Bieber, MD

Arch Dermatol. 1988;124(6):897-902.

Abstract
• Acitretin (etretin [Ro-10-1670]) is the major metabolite of etretinate with a much shorter elimination half-life. The drug was used in the treatment of 20 patients who had cutaneous lupus erythematosus. All patients responded to treatment, but in five, the result was unsatisfactory. In 15 patients, an excellent (total clearing) or good response (marked reduction of all lesions) was seen. In seven of them, acitretin was superior to previous therapy with antimalarials and/or systemic corticosteroids. In particular, five of six patients with subacute cutaneous lupus erythematosus showed complete clearing of their lesions, usually within two to four weeks. Side effects were the same as with etretinate. It is concluded that acitretin is a highly effective and well-tolerated drug in the treatment of cutaneous lupus erythematosus.

(Arch Dermatol 1988;124:897-902)

Author Affiliations
From the Department of Dermatology, University of Munich.

Footnotes
Accepted for publication Dec 11, 1987.

Reprint requests to Department of Dermatology, University of Munich, Frauenlobstrasse 9-11, D-8000 Munich 2, West Germany (Dr Ruzicka).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Review: Treatment of Cutaneous Lupus Erythematosus
Rothe and Kerdel
Lupus 1992;1:351-356.
ABSTRACT